FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2301-2304 November 29, 2007 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kjekshus, J. PubMed Citation

Hydroxymethylglutaryl–coenzyme A reductase inhibitors (statins) represent one of the most important pharmacologic advances in the prevention of cardiovascular disease in decades. Since the publication of the Scandinavian Simvastatin Survival Study in 1994,¹ several trials have demonstrated important benefits of statins in patients with established coronary disease. These findings have resulted in strong recommendations for the use of statins in clinical-practice guidelines.² Statins are one of the few classes of drugs that are embedded in clinical-performance measures for coronary artery disease, which indicates that clinicians should be considered remiss if they do not prescribe these agents for all their eligible patients.³

. . . [Full Text of this Article]

Source Information

From the Department of Medicine, Division of Cardiology, Denver Health Medical Center, Denver, and the Department of Medicine, Division of Cardiology, University of Colorado at Denver and Health Sciences Center, Aurora, CO.

This article (10.1056/NEJMe0707221) was published at www.nejm.org on November 5, 2007.

This article has been cited by other articles:

• (2007). Can Statins Benefit Elderly Patients with Ischemic Heart Failure?. JWatch General 2007: 8-8 [Full Text]